Description
Phase
Phase 3 - a treatment has shown activity against a particular disease, where it is either added to existing treatment or compared to the standard treatment.Inclusion and Exclusion Criteria
Please contact Anayansi Miloud to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- LAC and USC Medical Center, Los Angeles, California, 90033
- Coastal Integrative Cancer Care, San Luis Obispo, California, 93401
- California Cancer Associates for Research and Excellence, Fresno, California, 93720
- Ronald H. Yanagihara, MD, Gilroy, California, 95020
- San Jose Medical Group, San Jose, California, 95124
- Pacific Hematology Oncology Associates, San Francisco, California, 94115
-
Arizona
- Arizona Center for Cancer Care, Glendale, Arizona, 85306
-
Missouri
- Saint Luke's Cancer Institute, Kansas City, Missouri, 64111
-
Louisiana
- Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, 70809
-
Illinois
- Illinois Cancer Care, P.C., Peoria, Illinois, 61615
-
Indiana
- Indiana University Simon Cancer Center, Indianapolis, Indiana, 46202
-
Germany
- Universitaetsklinikum Ulm, Ulm, 89081
-
Italy
- A.O. R.N. "A.Cardarelli", Naples, 80131
- Seconda Universita degli Studi de Napoli, Napoli, 80131
- Ospedale di Rimini, Rimini, 47923
- Arcispidale S Maria Nuova, Reggio Emilia, 42123
-
France
- Centre Oscar Lambret, Lille, 59020
- Hopital Saint Antoine, Paris cedex 12, 75571
- Centre Eugene Marquis, Rennes cedex, 35042
-
Sweden
- Akademiska Sjukhuset, Uppsala, 75185
-
Czech Republic
- Klinika onkologie a radioteraie, Facultni nemocnice Hradec Kralove, Hradec Kralove, 50005
-
Spain
- Hospital General Universitario de Valencia, Valencia, 46014
- Hospital Universitario Morales Messeguer, Murcia, 30008
Powered by
SC CTSI